Human monoclonal antibodies that broadly target coronaviruses

An isolated monoclonal antibody or antigen binding fragment thereof, comprising a heavy chain variable (VH) region and a light chain variable region (VL) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3, and a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the VH and VL set forth as any one of:

• a) SEQ ID NOs:
• 17 and 21, respectively (COV44-79);
• b) SEQ ID NOs:
• 9 and 13, respectively (COV44-62);
• c) SEQ ID NOs:
• 1 and 5, respectively (COV89-22);
• d) SEQ ID NOs:
• 25 and 29, respectively (COV30-14);
• e) SEQ ID NOs:
• 33 and 37, respectively (COV72-37);
• f) SEQ ID NOs:
• 49 and 53, respectively (COV91-27);
• g) SEQ ID NOs:
• 41 and 45, respectively (COV93-03);
• h) SEQ ID NOs:
• 57 and 61, respectively (COV49-51);
• i) SEQ ID NOs:
• 65 and 69, respectively (COV44-74);
• j) SEQ ID NOs:
• 73 and 77, respectively (COV44-56);
• k) SEQ ID NOs:
• 81 and 85, respectively (COV44-26);
• l) SEQ ID NOs:
• 89 and 93, respectively (COV44-54);
• m) SEQ ID NOs:
• 97 and 101, respectively (COV23-01);
• n) SEQ ID NOs:
• 105 and 109, respectively (COV49-03);
• o) SEQ ID NOs:
• 113 and 117, respectively (COV49-04);
• p) SEQ ID NOs:
• 121 and 125, respectively (COV49-05);
• q) SEQ ID NOs:
• 129 and 133, respectively (COV49-06);
• r) SEQ ID NOs:
• 137 and 141, respectively (COV49-07);
• s) SEQ ID NOs:
• 145 and 149, respectively (COV49-18);
• t) SEQ ID NOs:
• 153 and 157, respectively (COV49-23);
• u) SEQ ID NOs:
• 161 and 165, respectively (COV49-28);
• v) SEQ ID NOs:
• 169 and 173, respectively (COV49-30);
• w) SEQ ID NOs:
• 177 and 181, respectively (COV49-33);
• x) SEQ ID NOs:
• 185 and 189, respectively (COV49-42);
• y) SEQ ID NOs:
• 193 and 197, respectively (COV49-47);
• z) SEQ ID NOs:
• 201 and 205, respectively (COV49-54);
• aa) SEQ ID NOs:
• 209 and 213, respectively (COV57-01);
• bb) SEQ ID NOs:
• 217 and 221, respectively (COV57-03);
• cc) SEQ ID NOs:
• 225 and 229, respectively (COV57-04);
• dd) SEQ ID NOs:
• 233 and 237, respectively (COV57-05);
• ee) SEQ ID NOs:
• 241 and 245, respectively (COV57-13);
• ff) SEQ ID NOs:
• 249 and 253, respectively (COV57-19);
• gg) SEQ ID NOs:
• 257 and 261, respectively (COV57-34);
• hh) SEQ ID NOs:
• 265 and 269, respectively (COV57-38);
• ii) SEQ ID NOs:
• 273 and 277, respectively (COV57-45);
• jj) SEQ ID NOs:
• 281 and 285, respectively (COV77-02);
• kk) SEQ ID NOs:
• 289 and 293, respectively (COV77-04);
• ll) SEQ ID NOs:
• 297 and 301, respectively (COV77-05);
• mm) SEQ ID NOs:
• 305 and 309, respectively (COV77-09);
• nn) SEQ ID NOs:
• 313 and 317, respectively (COV77-14);
• oo) SEQ ID NOs:
• 321 and 325, respectively (COV77-35);
• pp) SEQ ID NOs:
• 329 and 333, respectively (COV77-39);
• qq) SEQ ID NOs:
• 337 and 341, respectively (COV77-42);
• rr) SEQ ID NOs:
• 345 and 349, respectively (COV77-43);
• ss) SEQ ID NOs:
• 353 and 357, respectively (COV77-46);
• tt) SEQ ID NOs:
• 361 and 365, respectively (COV77-76);
• uu) SEQ ID NOs:
• 369 and 373, respectively (COV93-04);
• vv) SEQ ID NOs:
• 377 and 381, respectively (COV93-08);
• ww) SEQ ID NOs:
• 385 and 389, respectively (COV93-17);
• xx) SEQ ID NOs:
• 393 and 397, respectively (COV93-18);
• yy) SEQ ID NOs:
• 401 and 405, respectively (COV93-23);
• zz) SEQ ID NOs:
• 409 and 413, respectively (COV78-36);
• aaa) SEQ ID NOs:
• 417 and 421, respectively (COV93-38);
• bbb) SEQ ID NOs:
• 425 and 429, respectively (COV93-60);
• ccc) SEQ ID NOs:
• 433 and 437, respectively (COV93-61);
• ddd) SEQ ID NOs:
• 441 and 445, respectively (COV89-03);
• eee) SEQ ID NOs:
• 449 and 453, respectively (COV89-28);
• fff) SEQ ID NOs:
• 457 and 461, respectively (COV30-35);
• ggg) SEQ ID NOs:
• 465 and 469, respectively (COV30-80);
• hhh) SEQ ID NOs:
• 473 and 477, respectively (COV44-25);
• or
• iii) SEQ ID NOs:
• 481 and 485, respectively (COV44-37);
• and wherein the monoclonal antibody specifically binds to a coronavirus spike protein.